How I Choose Who to Transplant and Who Not to Transplant for MDS
Bart L. Scott, MD, Fred Hutchinson Cancer Research Center
Friday, September 8, 2017 11:00 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
While stem cell transplant is the only curative option for patients with myelodysplastic syndromes (MDS), there are many patients who are not eligible for this intervention due to considerable toxicity and lack of donor source. Dr. Scott will review indications for transplant in MDS patients including the role of age, prior therapy, and disease severity. He will also discuss the most appropriate way to prepare MDS patients for transplant, the role of conditioning intensity in stem cell transplantation, and the use of alternative donor sources.
About the Speaker
Bart L. Scott, MD, is the Associate Director of Myeloid Malignancies at the Seattle Cancer Care Alliance. He is Associate Professor at the University of Washington Medical Center and Associate Member at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Scott has presented numerous national and international lectures and has been a clinical investigator in National Institutes of Health clinical trials on treatment of MDS and myeloproliferative neoplasms (MPN). He is the recipient of the NIH Cancer Clinical Investigator Team Leadership Award. Dr. Scott earned his BS in Biology and Chemistry at the University of Alabama at Birmingham and his MD at the University of South Alabama in Mobile, Alabama. He completed his residency in internal medicine at the Johns Hopkins Hospital in Baltimore, Maryland, and his fellowship in medical oncology at the University of Washington in Seattle, Washington. He is a member of several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the American Society for Blood and Marrow Transplantation, and the International Society of Experimental Hematology. Dr. Scott serves on several national and local committees, teaches at the MDS clinic, and lectures on MPN and design of clinical trials to hematology residents and fellows. He has served as a reviewer for several peer-reviewed journals including New England Journal of Medicine, Blood, Journal of the National Comprehensive Cancer Network, Leukemia, Biology of Blood and Marrow Transplantation, and British Journal of Haemotology. He has authored numerous publications and several book chapters on MDS, myeloproliferative disorders, and stem cell transplantation.
back to top